secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001645113-23-000022
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NovoCure Q4 2022 net revenues $128.4M, full year $537.8M; LUNAR study meets primary endpoint
--------------------------------------------------------------------------------

- Full year 2022 net revenues $537.8M (+1% YoY); Q4 net revenues $128.4M (-4% YoY).
- Q4 net loss $37.3M ($0.36 loss per share); adjusted EBITDA $(10.5)M.
- Active patients 3,430 as of Dec 31, 2022 (-4% YoY); prescriptions 1,373 in Q4 (-4% YoY).
- Pivotal LUNAR study in NSCLC met primary overall survival endpoint; PANOVA-3 enrollment completed.
- Elected Dr. Allyson J. Ocean to Board of Directors; CE Mark for new array, limited market release in Europe.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511323000022/0001645113-23-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511323000022/nvcr-20230223.htm
  HTML page:      https://secwatch.observer/filing/0001645113-23-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer